About US
Contact us
-
German cost agency spurns Xalkori, KomboglyzeThe well-armed German pricing gatekeepers have dismissed two more Big Pharma drugs. Pfizer's ($PFE) lung cancer treatment Xalkori and the Bristol-Myers Squibb ($BMY)/AstraZeneca ($AZN) diabetes drug2013/2/22
-
Lyrica matches UCB drug in Pfizer's latest epilepsy trialPfizer's attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed a Phase III trial in adults with epilep2013/2/22
-
Pfizer demands rehearing in generic Reglan casePfizer ($PFE) asked the Alabama Supreme Court to think twice before allowing generics patients to sue branded drugmakers. The company filed for a rehearing yesterday, after the state's top court det2013/2/20
-
Italian antitrust agency probes alleged Roche-Novartis cartelItalian antitrust watchdogs have entered the Avastin-vs.-Lucentis fray. The Italian Competition Authority opened an investigation of Roche ($RHHBY) and Novartis ($NVS) on suspicion of a "cartel" des2013/2/20
-
GSK, Roche teaming with anti-doping agencyDrugmakers have watched their products become performance-enhancing tools for athletes for years. Steroids, human grown hormone and the now-notorious EPO, among others, came out of Big Pharma's labs2013/2/20
-
Novartis nabs another FDA-approved indication for everolimusTurns out, everolimus is becoming quite the franchise for Novartis ($NVS). Sold under the Afinitor and Votubia names for tumor treatment and as Zortress and Certican for transplant patients, everoli2013/2/19
-
Pfizer shutters CovX research operation in San DiegoPfizer ($PFE) is closing its CovX R&D operation in San Diego a little more than four years after buying the biotech company. About 100 jobs will be lost in the shudown2013/2/19
-
Takeda preps for first Actos trial now opening in L.A.The first trial of a lawsuit linking the diabetes drug Actos with bladder cancer is about to begin. As Bloomberg reports, jury selection starts today in Los Angeles, as Takeda Pharmaceuticals gears2013/2/19
-
UPDATED: Novartis nixes $78M non-compete with VasellaThe news of Daniel Vasella's $78 million payoff from Novartis couldn't have surfaced at a worse time. Once again, the Swiss drugmaker ($NVS) became a lightning rod for executive-pay watchdogs. And t2013/2/18
-
SFDA issues Technical Requirements for the Study of New Natural MedicinesTo improve the legal system for registration, standardize the registration of traditional Chinese medicines and natural medicines and encourage innovation, the State Food and Drug Administration (SFDA2013/2/17